DANVERS, Mass. Abiomed, a leading provider of breakthrough heart support technologies, announced today that it has submitted U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplemental ...
The US Food and Drug Administration (FDA)-approved labeling for the Impella 5.0 and Impella LD heart pumps (Abiomed) has been expanded to allow for longer support time in critically ill patients, the ...
ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed. In more than ...
DANVERS, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, announced today that the Impella 5.5™ heart ...
Abiomed has announced a recall of some Impella 5.5 with SmartAssist systems after receiving complaints from customers reporting purge fluid leaking from the purge sidearm of the pump. The Impella 5.5 ...
Lately, Abiomed investors have seen their shares bounce around like a kid on a trampoline, mainly because the company is at an unpredictable crossroads. The shares are trading at a high multiple of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results